BRITEPath- Phase 2

Summary

BRITEPath- Phase 2 is a clinical trial^[1].

Key Facts

• BRITEPath- Phase 2 is in the country of United States^[2].
• BRITEPath- Phase 2's instance of is recorded as clinical trial^[3].
• BRITEPath- Phase 2's start time is recorded as +2020-11-05T00:00:00Z^[4].
• BRITEPath- Phase 2's end time is recorded as +2022-04-30T00:00:00Z^[5].
• BRITEPath- Phase 2's contributor to the creative work or subject is recorded as National Institute of Mental Health^[6].
• BRITEPath- Phase 2's sponsor is recorded as University of Pittsburgh^[7].
• BRITEPath- Phase 2's main subject is recorded as major depressive disorder^[8].
• BRITEPath- Phase 2's main subject is recorded as suicidal ideation^[9].
• BRITEPath- Phase 2's number of participants is recorded as {'unit': '1', 'amount': '+100'}^[10].
• BRITEPath- Phase 2's title is recorded as The Center for Enhancing Treatment & Utilization for Depression and Emergent Suicidality Phase 2-Study 3-BRITEPath^[11].
• BRITEPath- Phase 2's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+12'}^[12].
• BRITEPath- Phase 2's ClinicalTrials.gov ID is recorded as NCT04672798^[13].
• BRITEPath- Phase 2's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+26'}^[14].
• BRITEPath- Phase 2's research site is recorded as Henry Ford Health^[15].
• BRITEPath- Phase 2's research subject recruitment status is recorded as recruiting^[16].
• BRITEPath- Phase 2's study type is recorded as interventional study^[17].